Non-inferiority, Randomised, Open-label Clinical Trial on the Effectiveness of Transurethral Microwave Thermotherapy Compared to Prostatic Artery Embolisation in Reducing Severe Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia:...

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2024 Sep 2

PMID 39223593

Authors

Anna Kristensen-Alvarez

Mikkel Fode

Hein Vincent Stroomberg

Kurt Kroyer Nielsen

Albert Arch

Lars Birger Lonn

Mikkel Taudorf

Steven John Widecrantz

Andreas Roder

Affiliations

Soon will be listed here.

Abstract

Background: One-fourth of men older than 70 years have lower urinary tract symptoms (LUTS) that impair their quality of life. Transurethral resection of the prostate (TURP) is considered the gold standard for surgical treatment of LUTS caused by benign prostatic hyperplasia (BPH) that cannot be managed conservatively or pharmacologically. However, TURP is only an option for patients fit for surgery and can result in complications. Transurethral microwave thermotherapy (TUMT) and prostatic artery embolisation (PAE) are alternative minimally invasive surgical therapies (MISTs) performed in an outpatient setting. Both treatments have shown to reduce LUTS with a similar post-procedure outcome in mean International Prostate Symptom Score (IPSS). It is however still unknown if TUMT and PAE perform equally well as they have never been directly compared in a randomised clinical trial. The objective of this clinical trial is to assess if PAE is non-inferior to TUMT in reducing LUTS secondary to BPH.

Methods: This study is designed as a multicentre, non-inferiority, open-label randomised clinical trial. Patients will be randomised with a 1:1 allocation ratio between treatments. The primary outcome is the IPSS of the two arms after 6 months. The primary outcome will be evaluated using a 95% confidence interval against the predefined non-inferiority margin of + 3 points in IPSS. Secondary objectives include the comparison of patient-reported and functional outcomes at short- and long-term follow-up. We will follow the patients for 5 years to track long-term effect. Assuming a difference in mean IPSS after treatment of 1 point with an SD of 5 and a non-inferiority margin set at the threshold for a clinically non-meaningful difference of + 3 points, the calculated sample size was 100 patients per arm. To compensate for 10% dropout, the study will include 223 patients.

Discussion: In this first randomised clinical trial to compare two MISTs, we expect non-inferiority of PAE to TUMT. The most prominent problems with MIST BPH treatments are the unknown long-term effect and the lack of proper selection of candidates for a specific procedure. With analysis of the secondary outcomes, we aspire to contribute to a better understanding of durability and provide knowledge to guide treatment decisions.

Trial Registration: ClinicalTrials.gov NCT05686525. Registered on January 17, 2023, https://clinicaltrials.gov/study/NCT05686525 .

Citing Articles

Prostatic Artery Embolization in Elderly Comorbid Patients with Benign Prostatic Hyperplasia: Safety, Efficacy, and Predictive Factors of Clinical Failure.

Zorzi F, Rossin G, Digregorio M, Lavecchia S, Piasentin A, Traunero F J Pers Med. 2025; 15(1).

PMID: 39852215 PMC: 11767102. DOI: 10.3390/jpm15010023.

References

Pisco J, Bilhim T, Pinheiro L, Fernandes L, Pereira J, Costa N . Medium- and Long-Term Outcome of Prostate Artery Embolization for Patients with Benign Prostatic Hyperplasia: Results in 630 Patients. J Vasc Interv Radiol. 2016; 27(8):1115-22. DOI: 10.1016/j.jvir.2016.04.001. View

McNicholas T, Kirby R . Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011; 2011. PMC: 3217770. View

Malling B, Roder M, Brasso K, Forman J, Taudorf M, Lonn L . Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2018; 29(1):287-298. DOI: 10.1007/s00330-018-5564-2. View

Martinez Diaz S, Bhojani N, Elterman D, Zorn K, Kaplan S, Kohler T . Development of a North American coordinated registry network for surgical treatment of benign prostatic hyperplasia. World J Urol. 2022; 40(12):2991-2999. DOI: 10.1007/s00345-022-04164-3. View

Hoffman R, MacDonald R, Monga M, Wilt T . Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU Int. 2004; 94(7):1031-6. DOI: 10.1111/j.1464-410X.2004.05099.x. View

Hashim H, Abrams P . Transurethral resection of the prostate for benign prostatic obstruction: will it remain the gold standard?. Eur Urol. 2014; 67(6):1097-1098. DOI: 10.1016/j.eururo.2014.12.022. View

Barry M, Cantor A, Roehrborn C . Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. J Urol. 2012; 189(3):987-92. PMC: 3932029. DOI: 10.1016/j.juro.2012.08.257. View

Rubeinstein J, McVary K . Transurethral microwave thermotherapy for benign prostatic hyperplasia. Int Braz J Urol. 2005; 29(3):251-63. DOI: 10.1590/s1677-55382003000300013. View

Dindo D, Demartines N, Clavien P . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205-13. PMC: 1360123. DOI: 10.1097/01.sla.0000133083.54934.ae. View

10.

Carnevale F, Iscaife A, Yoshinaga E, Moreira A, Antunes A, Srougi M . Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis. Cardiovasc Intervent Radiol. 2015; 39(1):44-52. DOI: 10.1007/s00270-015-1202-4. View

11.

Hansen B, Flyger H, Brasso K, Schou J, Nordling J, Andersen J . [Validation of the patient-administered Danish Prostate Symptom Score Schedule]. Ugeskr Laeger. 1997; 159(5):591-7. View

12.

Julious S . Sample sizes for clinical trials with normal data. Stat Med. 2004; 23(12):1921-86. DOI: 10.1002/sim.1783. View

13.

Gao Y, Huang Y, Zhang R, Yang Y, Zhang Q, Hou M . Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate--a prospective, randomized, and controlled clinical trial. Radiology. 2014; 270(3):920-8. DOI: 10.1148/radiol.13122803. View

14.

Rosen R, Cappelleri J, Gendrano 3rd N . The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002; 14(4):226-44. DOI: 10.1038/sj.ijir.3900857. View

15.

Carnevale F, de Assis A, Moreira A . Prostatic Artery Embolization: Equipment, Procedure Steps, and Overcoming Technical Challenges. Tech Vasc Interv Radiol. 2020; 23(3):100691. DOI: 10.1016/j.tvir.2020.100691. View

16.

Svarc P, Taudorf M, Nielsen M, Stroomberg H, Roder M, Lonn L . Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. Diagnostics (Basel). 2020; 10(9). PMC: 7555179. DOI: 10.3390/diagnostics10090659. View

17.

Abt D, Mullhaupt G, Mordasini L, Gusewell S, Markart S, Zumstein V . Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial. BJU Int. 2018; 124(1):134-144. DOI: 10.1111/bju.14632. View

18.

Pisco J, Rio Tinto H, Pinheiro L, Bilhim T, Duarte M, Fernandes L . Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol. 2013; 23(9):2561-72. DOI: 10.1007/s00330-012-2714-9. View

19.

Hoffman R, Monga M, Elliot S, MacDonald R, Wilt T . Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007; (4):CD004135. DOI: 10.1002/14651858.CD004135.pub2. View

20.

Janssen M, Bonsel G, Luo N . Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries. Pharmacoeconomics. 2018; 36(6):675-697. PMC: 5954015. DOI: 10.1007/s40273-018-0623-8. View